Invitrogen™ LeukoLOCK™ Total RNA Isolation System

Ref.: BL-RE-090057Manufacturer ref.: AM1923 20 preps
€1,762.00 excl. VAT

The RNA total isolation system LeukoLOCK™ is an innovative method for cell fractionation of total blood and stabilization and extraction of total RNA from the leukocyte population. The kit is composed of a kit of...

Content and storage
Keep PBS 1X pH 7.4, RNA solutionlater;™, le bouchon de septum en caoutchouc, le connecteur à glissement blanc, la pointe de transfert, le filtre LeukoLOCK™, la solution d’élution, la solution de liaison ⁄ lyse LeukoLOCK™, la solution d’ajustement du pH LeukoLOCK™, les tubes de traitement, le concentrat de solution de lavage 1, le concentrat de solution de lavage 2 ⁄ 3 et l’eau exempte de nucléase à température ambiante. Conserver les microbilles de liaison à l’ARN à 4°C. Conserver le tampon de DNase 1X LeukoLOCK™, la protéinase K et la DNase TURBO™ à -20°C.
Isolation Technology
Leukocyte capture filter, Magnetic microbead
Type of sample
Cells, blood
End product type
Total RNA
High-throughput compatibility
Not high-throughput compatible (manual)
Brand
Invitrogen

The RNA total isolation system LeukoLOCK™ is an innovative method for cell fractionation of total blood and stabilization and extraction of total RNA from the leukocyte population. The kit is composed of a kit of...

The RNA total isolation system LeukoLOCK™ is an innovative method for cell fractionation of total blood and stabilization and extraction of total RNA from the leukocyte population. The kit consists of a LeukoLOCK stabilization and fractionation kit (also available separately; Cat. No. AM1933) and a total LeukoLOCK isolation kit.

LeukoLOCK is optimized for use with human blood. Blood is a cellular information storage device; however, the presence of globin mRNA in the RNA prepared from whole blood may interfere with downstream expression profiling applications. The LeukoLOCK system uses filter-based leukocyte depletion technology to isolate leukocytes from total blood and RNAlater™ solution to stabilize cells on the filter. By excluding red blood cells, the purified RNA from the captured leukocytes is intrinsically depleted to globin mRNA, which improves the usefulness of samples for expression profiling and other applications.

Leukocyte capture and stabilization

A 9-10 ml sample of anti-coagulated blood passes through a LeukoLOCK filter, which captures the total leukocyte population while eliminating red blood cells (including reticulocytes), platelets and plasma. After rinsing with phosphate buffered saline, the filter is rinsed with RNAlater to stabilize the RNA in the captured leukocytes. The RNA can be isolated immediately or stabilized cells can be maintained for several days at room temperature or for longer periods at –20°C or –80°C.

Purification of the RNA is performed by first disrupting cells captured in a guanidinium dethiocyanate solution that releases the RNA while simultaneously inactivating the nucleases. Cell lysate is taken and treated briefly with K proteinase. The RNA is then purified from lysate using MagMAX magnetic microbead technology for washing, followed by DNase treatment (with DNase TURBO™) and final cleaning.

Biochip and quantitative RT-PCR expression studies have validated the relevance of purified l的RNA for reliable profiling of transcriptomas. Compared to the RNA treated with a commonly used blood isolation procedure of RNA, the RNA isolated with the LeukoLOCK system produces a longer median aRNA after amplification and a higher percentage of calls present without requiring further post-extraction steps to eliminate the mRNA of globin. Since globin aRNA accounts for 25-40% of the peak of aRNA from total blood, the yield of total RNA is naturally lower with methods that exhaust undesirable globin transcripts. The RNA amplified after LeukoLOCK purification provides a greater sensitivity of the matrix due to the dramatic reduction of competing globin transcripts.

Recovery varies from donor to donor, but is generally 10-20 μg d的RNA per 9-10 ml of total blood. The recovery of the LeukoLOCK-derived L-RNA contains less than one tenth of the amount of alpha and beta globin derived from reticulocytes present in typical d-RNA samples from unfractionated total blood.

Not high-throughput compatible (manual)

Purification and analysis of DNA and RNA, extraction of RNA, isolation of total RNA, total RNA of animal cells and tissues, total RNA of blood

Fraction the leukocytes of the whole blood in...

Fraction the leukocytes of the whole blood within minutes

Total leukocyte extract

Total leukocyte extract

No further step of reducing...

No further globin reduction step is required

Stabilizes the RNA to preserve the profile...

Stabilizes the RNA to preserve the expression profile.

Keep leukocytes at room temperature...

Keep leukocytes at room temperature for several days.

Technical specifications

General
BrandInvitrogen
Supplier ref. (Fisher Scientific)10506945
Specifications
Isolation TechnologyLeukocyte capture filter, Magnetic microbead
Type of sampleCells, blood
End product typeTotal RNA
High-throughput compatibilityNot high-throughput compatible (manual)
For use with (application)Biochip analysis, real-time quantitative PCR (qPCR), reverse transcriptase PCR (RT-PCR), nuclease protection assays, Northern transfer, library construction d
No. of reactions20 preparations
Preparation scale> 1 ml blood samples (large scale)
Product rangeAmbion™, LeukoLOCK™
Quantity20 preps
Quantity of start-up equipmentUp to 10 ml of total blood
TargetTotal RNA
Storage and shipping
Content and storageKeep PBS 1X pH 7.4, RNA solutionlater;TM, rubber septum cap, white slip connector, transfer tip, LeukoLOCK™ filter, elution solution, LeukoLOCK™ ⁄ lysis binding solution, LeukoLOCK™ pH adjustment solution, milking tubes

Origin and customs

Manufacturer ref.AM1923
Country of originUnited States
HS customs code3822 90 00 00
A question or a specific configuration?
Contact us for a quote.